nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
|
Trillsch, F. |
|
|
25 |
7 |
p. 1320-1327 |
artikel |
2 |
A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers
|
Ling, Z.Q. |
|
|
25 |
7 |
p. 1363-1372 |
artikel |
3 |
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
|
Arcaini, L. |
|
|
25 |
7 |
p. 1404-1410 |
artikel |
4 |
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
|
Pant, S. |
|
|
25 |
7 |
p. 1416-1421 |
artikel |
5 |
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
|
Gralla, R.J. |
|
|
25 |
7 |
p. 1333-1339 |
artikel |
6 |
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
|
Aapro, M. |
|
|
25 |
7 |
p. 1328-1333 |
artikel |
7 |
Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis
|
Schmid, D. |
|
|
25 |
7 |
p. 1293-1311 |
artikel |
8 |
Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival
|
Helleday, T. |
|
|
25 |
7 |
p. 1253-1255 |
artikel |
9 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
|
Glynne-Jones, R. |
|
|
25 |
7 |
p. 1356-1362 |
artikel |
10 |
Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort
|
Tikk, K. |
|
|
25 |
7 |
p. 1422-1428 |
artikel |
11 |
Corrections to “A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma”
|
Evens, A.M. |
|
|
25 |
7 |
p. 1449 |
artikel |
12 |
Editorial Board
|
|
|
|
25 |
7 |
p. ii-iii |
artikel |
13 |
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
|
Hesketh, P.J. |
|
|
25 |
7 |
p. 1340-1346 |
artikel |
14 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
|
Douillard, J.Y. |
|
|
25 |
7 |
p. 1346-1355 |
artikel |
15 |
Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival
|
Ishikawa, T. |
|
|
25 |
7 |
p. 1379-1384 |
artikel |
16 |
Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype
|
Fallah, M. |
|
|
25 |
7 |
p. 1397-1404 |
artikel |
17 |
Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments
|
Uzan, C. |
|
|
25 |
7 |
p. 1312-1319 |
artikel |
18 |
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
|
Polo, V. |
|
|
25 |
7 |
p. 1283-1293 |
artikel |
19 |
Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology
|
Pallis, A.G. |
|
|
25 |
7 |
p. 1270-1283 |
artikel |
20 |
Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?
|
Andrews, P.L.R. |
|
|
25 |
7 |
p. 1258-1259 |
artikel |
21 |
New cancer drugs: the Italian unsatisfactory solution
|
Tartarone, A. |
|
|
25 |
7 |
p. 1448 |
artikel |
22 |
Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma
|
Gill, H. |
|
|
25 |
7 |
p. 1391-1397 |
artikel |
23 |
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
|
Grob, J.-J. |
|
|
25 |
7 |
p. 1428-1436 |
artikel |
24 |
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
|
Propper, D. |
|
|
25 |
7 |
p. 1384-1390 |
artikel |
25 |
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
|
Argiris, A. |
|
|
25 |
7 |
p. 1410-1416 |
artikel |
26 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF †
|
Chauffert, B. |
|
|
25 |
7 |
p. 1442-1447 |
artikel |
27 |
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
|
Bajetta, E. |
|
|
25 |
7 |
p. 1373-1378 |
artikel |
28 |
Smarter drugs emerging in pancreatic cancer therapy
|
Kleger, A. |
|
|
25 |
7 |
p. 1260-1270 |
artikel |
29 |
Table of Contents
|
|
|
|
25 |
7 |
p. iv-vi |
artikel |
30 |
The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type
|
Prat, J. |
|
|
25 |
7 |
p. 1255-1258 |
artikel |
31 |
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
|
Urner-Bloch, U. |
|
|
25 |
7 |
p. 1437-1441 |
artikel |